Brief: Verastem Oncology Receives FDA Orphan Drug Designation For Avutometinib And Defactinib

Verastem

29/07/2024 21:17

July 29 (Reuters) - Verastem Inc  VSTM.O :
    * VERASTEM ONCOLOGY RECEIVES FDA ORPHAN DRUG DESIGNATION FOR
AVUTOMETINIB AND DEFACTINIB FOR THE TREATMENT OF PANCREATIC
CANCER
    * VERASTEM INC - EXPECT TO REPORT UPDATED DATA FROM ONGOING
RAMP
205 TRIAL IN FIRST-LINE METASTATIC PANCREATIC CANCER IN Q1 2025
    * VERASTEM INC - TO REPORT UPDATED RAMP 205 DATA IN Q1 2025

Source text for Eikon:  ID:nBwbMvhNfa 
Further company coverage:  VSTM.O 

 ((Reuters.Briefs@thomsonreuters.com;))